Quince Therapeutics, Inc.
For the period ended Mar 31, 2026. Filed May 11, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 11, 2026
QNCX$31.73+8.1%Stored close · as of Oct 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows (Unaudited)
CONDENSED CONSOLI DATED STATEMENTS OF CASH FLOWS
(In thousands)
| For the Three Months Ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Cash flows from operating activities | ||
| Net income (loss) | $35,912 | $(15,030) |
| Adjustments to reconcile net income (loss) to net cash used in operating activities: | ||
| Stock based compensation | 1,286 | 1,386 |
| Depreciation and amortization | 36 | 32 |
| Change in the fair value of contingent consideration liabilities | (64,330) | 1,924 |
| Change in fair value of debt, net | (12,197) | 391 |
| Change in fair value of warrants | (31,116) | — |
| Gain on settlement of accounts payable | (2,584) | — |
| Intangible asset impairment charge | 67,808 | — |
| Amortization of discount on available-for-sale investments | (62) | (355) |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (3,639) | 944 |
| Right of use assets, operating leases and operating lease liabilities | 28 | 24 |
| Other assets | 1,782 | 163 |
| Accounts payable | 5,911 | 22 |
| Accrued expenses and other current liabilities | (7,163) | 899 |
| Other liabilities | 701 | (1) |
| Net cash used in operating activities | (7,627) | (9,601) |
| Cash flow from investing activities: | ||
| Purchase of investments | — | (1,954) |
| Proceeds from maturities of investments | 12,000 | 13,000 |
| Purchase of property and equipment | — | (148) |
| Net cash provided by investing activities | 12,000 | 10,898 |
| Cash flows from financing activities: | ||
| Issuance of common stock in connection with the ATM offerings, net of issuance costs | 14,988 | — |
| Proceeds from issuance of common stock upon exercise of stock options | — | 87 |
| Repayment of debt | (5,545) | — |
| Net cash provided by financing activities | 9,443 | 87 |
| Effect of exchange rate changes on cash | (1,462) | 175 |
| Net increase in cash and cash equivalents | 12,354 | 1,559 |
| Cash and cash equivalents at beginning of period | 5,809 | 6,212 |
| Cash and cash equivalents at end of period | $18,163 | $7,771 |
| Supplemental disclosures of cash flow and non-cash information: | ||
| Interest payment on debt | $(29) | $(53) |
| Noncash exercise of pre-funded warrants | $340 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.